Akash S. Patel - 02 Apr 2025 Form 4 Insider Report for NET Power Inc. (NPWR)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Apr 2025, 21:57:51 UTC
Prior SEC filing
26 Nov 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ James Mahon, attorney-in-fact

Key filing fact

Akash S. Patel filed Form 4 for NET Power Inc. (NPWR) on 04 Apr 2025.

Key facts

  • This page summarizes Akash S. Patel's Form 4 filing for NET Power Inc. (NPWR).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 04 Apr 2025, 21:57.

Change

  • Previous filing in this sequence was filed on 26 Nov 2024.
  • Current net transaction value: -$16,871.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NPWR transaction

Restricted Stock Units

Award

Transaction value
$0
Shares
+117,757
Change %
+35%
Price
$0.000000
Shares after
457,790
Date
02 Apr 2025
Ownership
Direct
Footnotes
F1
NPWR transaction

Class A Common Stock

Sale

Transaction value
$16,871
Shares
-7,359
Change %
-100%
Price
$2.29
Shares after
0
Date
03 Apr 2025
Ownership
Direct
Footnotes
F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NPWR transaction Derivative

Performance Stock Units

Award

Transaction value
$0
Shares
+117,757
Change %
+352%
Price
$0.000000
Shares after
151,208
Date
02 Apr 2025
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
117,757
Exercise price
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Restricted stock units that vest in three equal installments on each anniversary of April 2, 2025, subject to continued employment.

Footnote F2

The Reporting Person was issued 7,359 net shares of Class A Common Stock upon the vesting of 11,151 restricted stock units on April 2, 2025. The sale of such shares was effected pursuant to a Rule 10b5-1 trading plan.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.25 to $2.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F4

The Reporting Person will receive a number of shares of Class A common stock equal to 50% of the number of PSUs upon attainment of a 10% compound annual growth rate ("CAGR") of the 30-day volume weighted average price ("VWAP") of a share of Class A common stock on April 2, 2028 as compared to the VWAP of a share of Class A common stock on April 2, 2025. The Reporting Person will receive a number of shares of Class A common stock equal to 100% of the number of PSUs upon attainment of a 12% CAGR of the VWAP of a share of Class A common stock on April 2, 2028 as compared to the VWAP of a share of Class A common stock on April 2, 2025. The Reporting Person will receive a number of shares of Class A common stock equal to 200% of the number of PSUs upon attainment of a 15% CAGR of the VWAP of a share of Class A common stock on April 2, 2028 as compared to the VWAP of a share of Class A common stock on April 2, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .